Dataset from A Multi-centre Phase IIa Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK3196165 in Subjects With Inflammatory Hand Osteoarthritis

This is a randomized, Phase IIa, multicentre, double-blind, placebo-controlled parallel group
study with the primary objective to assess the efficacy potential of GSK3196165 on pain, in
subjects with active inflammatory hand osteoarthritis (HOA).

Approximately 40 subjects will be enrolled into the study, following a screening period of up
to 4 weeks. The total treatment period will be 12 weeks, with the follow up period completing
at Week 22. At least 40 subjects will be randomized across the two treatment arms, to either
placebo or GSK3196165 in a 1:1 ratio.